IL6 and neoplasm: ICIs exert their effects on the immune microenvironment surrounding tumors, and it has been demonstrated that CD8+ T lymphocytes, B cells, IL-6, and tertiary lymphoid structures (TLS) within tumor tissue all play a role in influencing the prognosis of ICI therapy for tumors (75–77).